InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,221.34
(
0.00%
)
US TECH 100
17,735.20
(
0.07%
)
Dow Jones
39,420.77
(
-0.03%
)
Brent Oil
82.26
(
-1.14%
)
Bitcoin
61,375.33
(
-2.43%
)
Post# of 251819
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119629
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: JohnWayne post# 205052

Friday, 02/17/2017 10:46:32 AM

Friday, February 17, 2017 10:46:32 AM

Post# of 251819
AZN +1.5% on phase-3 Lynparza data in BRCA+ breast cancer:

http://finance.yahoo.com/news/lynparza-olaparib-meets-primary-endpoint-120000191.html

AstraZeneca today announced positive results from its Phase III OlympiAD trial comparing LYNPARZA (olaparib) tablets (300mg twice daily) to physician’s choice of a standard of care chemotherapy in the treatment of patients with HER2-negative metastatic breast cancer harboring germline BRCA1 or BRCA2 mutations. Patients treated with LYNPARZA showed a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) compared with those who received chemotherapy (capecitabine, vinorelbine or eribulin).

AstraZeneca will be working with regulatory authorities to make LYNPARZA available to patients with this type of breast cancer.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up